Geron (NASDAQ:GERN) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Geron (NASDAQ:GERN) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $9.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners began coverage on shares of Geron in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Barclays upgraded shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th. Finally, Scotiabank assumed coverage on Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.15.

Geron Trading Down 1.5 %

Shares of Geron stock opened at $3.92 on Tuesday. The firm has a 50-day simple moving average of $4.08 and a two-hundred day simple moving average of $4.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The company has a market cap of $2.37 billion, a P/E ratio of -12.25 and a beta of 0.51.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. During the same quarter in the prior year, the firm posted ($0.08) EPS. Geron’s quarterly revenue was up 17138.4% compared to the same quarter last year. As a group, equities analysts predict that Geron will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Geron

Several hedge funds and other institutional investors have recently made changes to their positions in GERN. Darwin Global Management Ltd. purchased a new stake in shares of Geron in the 2nd quarter valued at approximately $106,185,000. Renaissance Technologies LLC purchased a new position in Geron in the second quarter worth approximately $3,315,000. RTW Investments LP acquired a new stake in Geron during the third quarter worth $200,268,000. Algert Global LLC acquired a new stake in Geron during the second quarter worth $539,000. Finally, Farallon Capital Management LLC raised its position in Geron by 124.6% in the second quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock valued at $71,389,000 after purchasing an additional 9,342,000 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.